Acitretin Use in Dermatology
Background: Acitretin has been used for the treatment of severe psoriasis for over 20 years. Objective: The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation....
Gespeichert in:
| Veröffentlicht in: | Journal of Cutaneous Medicine and Surgery 2017-11, Vol.21 (3_suppl), p.2S-12S |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12S |
|---|---|
| container_issue | 3_suppl |
| container_start_page | 2S |
| container_title | Journal of Cutaneous Medicine and Surgery |
| container_volume | 21 |
| creator | Guenther, Lyn C. Kunynetz, Rod Lynde, Charles W. Sibbald, R. Gary Toole, John Vender, Ronald Zip, Catherine |
| description | Background:
Acitretin has been used for the treatment of severe psoriasis for over 20 years.
Objective:
The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation.
Methods:
A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. A panel of Canadian dermatologists developed a clinical pathway using a case-based approach, focusing on specific patient features.
Results:
The clinical pathway covers plaque psoriasis with hyperkeratotic plantar disease, palmoplantar pustulosis, hyperkeratotic hand dermatitis, lichen planus, lamellar ichthyosis, and hidradenitis suppurativa.
Conclusion:
The recommendations in our clinical pathway reflect the current use of acitretin in Canada for severe psoriasis and other disorders of keratinisation. |
| doi_str_mv | 10.1177/1203475417733414 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1943650303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1203475417733414</sage_id><sourcerecordid>2157487381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-fd5b591031e1ce75fb2848add347c3188df5d53837c75d4bec47c3150f033bd03</originalsourceid><addsrcrecordid>eNp1kM1PwzAMxSMEYmNw54AQEhcuhbiOl_Q4jU9pEhd2jtoknTq160jaw_57MjZAmsTJlv3ze9Zj7BL4PYCUD5ByFJJE7BEFiCM2hDFQIoFnx7GP62S7H7CzEJaccwASp2yQqoxSRBqyq4mpOu-6anUzD-4mlkfnm7xr63axOWcnZV4Hd7GvIzZ_fvqYviaz95e36WSWGBxTl5SWCsqAIzgwTlJZpEqo3Nr4m0FQypZkCRVKI8mKwpnvOfGSIxaW44jd7XTXvv3sXeh0UwXj6jpfubYPGjIRjThGfMRuD9Bl2_tV_E6nQFIoiQoixXeU8W0I3pV67asm9xsNXG-T04fJxZPrvXBfNM7-HvxEFYFkB4R84f5c_xX8AiVIceU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157487381</pqid></control><display><type>article</type><title>Acitretin Use in Dermatology</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Guenther, Lyn C. ; Kunynetz, Rod ; Lynde, Charles W. ; Sibbald, R. Gary ; Toole, John ; Vender, Ronald ; Zip, Catherine</creator><creatorcontrib>Guenther, Lyn C. ; Kunynetz, Rod ; Lynde, Charles W. ; Sibbald, R. Gary ; Toole, John ; Vender, Ronald ; Zip, Catherine</creatorcontrib><description>Background:
Acitretin has been used for the treatment of severe psoriasis for over 20 years.
Objective:
The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation.
Methods:
A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. A panel of Canadian dermatologists developed a clinical pathway using a case-based approach, focusing on specific patient features.
Results:
The clinical pathway covers plaque psoriasis with hyperkeratotic plantar disease, palmoplantar pustulosis, hyperkeratotic hand dermatitis, lichen planus, lamellar ichthyosis, and hidradenitis suppurativa.
Conclusion:
The recommendations in our clinical pathway reflect the current use of acitretin in Canada for severe psoriasis and other disorders of keratinisation.</description><identifier>ISSN: 1203-4754</identifier><identifier>EISSN: 1615-7109</identifier><identifier>DOI: 10.1177/1203475417733414</identifier><identifier>PMID: 28952335</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Acitretin - adverse effects ; Acitretin - therapeutic use ; Contraindications, Drug ; Hidradenitis Suppurativa - drug therapy ; Humans ; Ichthyosis, Lamellar - drug therapy ; Keratoderma, Palmoplantar - drug therapy ; Keratolytic Agents - adverse effects ; Keratolytic Agents - therapeutic use ; Lichen Planus - drug therapy ; Patient Selection ; Psoriasis ; Psoriasis - drug therapy ; Skin Diseases - drug therapy</subject><ispartof>Journal of Cutaneous Medicine and Surgery, 2017-11, Vol.21 (3_suppl), p.2S-12S</ispartof><rights>The Author(s) 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-fd5b591031e1ce75fb2848add347c3188df5d53837c75d4bec47c3150f033bd03</citedby><cites>FETCH-LOGICAL-c365t-fd5b591031e1ce75fb2848add347c3188df5d53837c75d4bec47c3150f033bd03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1203475417733414$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1203475417733414$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>313,314,780,784,792,21819,27922,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28952335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guenther, Lyn C.</creatorcontrib><creatorcontrib>Kunynetz, Rod</creatorcontrib><creatorcontrib>Lynde, Charles W.</creatorcontrib><creatorcontrib>Sibbald, R. Gary</creatorcontrib><creatorcontrib>Toole, John</creatorcontrib><creatorcontrib>Vender, Ronald</creatorcontrib><creatorcontrib>Zip, Catherine</creatorcontrib><title>Acitretin Use in Dermatology</title><title>Journal of Cutaneous Medicine and Surgery</title><addtitle>J Cutan Med Surg</addtitle><description>Background:
Acitretin has been used for the treatment of severe psoriasis for over 20 years.
Objective:
The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation.
Methods:
A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. A panel of Canadian dermatologists developed a clinical pathway using a case-based approach, focusing on specific patient features.
Results:
The clinical pathway covers plaque psoriasis with hyperkeratotic plantar disease, palmoplantar pustulosis, hyperkeratotic hand dermatitis, lichen planus, lamellar ichthyosis, and hidradenitis suppurativa.
Conclusion:
The recommendations in our clinical pathway reflect the current use of acitretin in Canada for severe psoriasis and other disorders of keratinisation.</description><subject>Acitretin - adverse effects</subject><subject>Acitretin - therapeutic use</subject><subject>Contraindications, Drug</subject><subject>Hidradenitis Suppurativa - drug therapy</subject><subject>Humans</subject><subject>Ichthyosis, Lamellar - drug therapy</subject><subject>Keratoderma, Palmoplantar - drug therapy</subject><subject>Keratolytic Agents - adverse effects</subject><subject>Keratolytic Agents - therapeutic use</subject><subject>Lichen Planus - drug therapy</subject><subject>Patient Selection</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Skin Diseases - drug therapy</subject><issn>1203-4754</issn><issn>1615-7109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1PwzAMxSMEYmNw54AQEhcuhbiOl_Q4jU9pEhd2jtoknTq160jaw_57MjZAmsTJlv3ze9Zj7BL4PYCUD5ByFJJE7BEFiCM2hDFQIoFnx7GP62S7H7CzEJaccwASp2yQqoxSRBqyq4mpOu-6anUzD-4mlkfnm7xr63axOWcnZV4Hd7GvIzZ_fvqYviaz95e36WSWGBxTl5SWCsqAIzgwTlJZpEqo3Nr4m0FQypZkCRVKI8mKwpnvOfGSIxaW44jd7XTXvv3sXeh0UwXj6jpfubYPGjIRjThGfMRuD9Bl2_tV_E6nQFIoiQoixXeU8W0I3pV67asm9xsNXG-T04fJxZPrvXBfNM7-HvxEFYFkB4R84f5c_xX8AiVIceU</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Guenther, Lyn C.</creator><creator>Kunynetz, Rod</creator><creator>Lynde, Charles W.</creator><creator>Sibbald, R. Gary</creator><creator>Toole, John</creator><creator>Vender, Ronald</creator><creator>Zip, Catherine</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201711</creationdate><title>Acitretin Use in Dermatology</title><author>Guenther, Lyn C. ; Kunynetz, Rod ; Lynde, Charles W. ; Sibbald, R. Gary ; Toole, John ; Vender, Ronald ; Zip, Catherine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-fd5b591031e1ce75fb2848add347c3188df5d53837c75d4bec47c3150f033bd03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acitretin - adverse effects</topic><topic>Acitretin - therapeutic use</topic><topic>Contraindications, Drug</topic><topic>Hidradenitis Suppurativa - drug therapy</topic><topic>Humans</topic><topic>Ichthyosis, Lamellar - drug therapy</topic><topic>Keratoderma, Palmoplantar - drug therapy</topic><topic>Keratolytic Agents - adverse effects</topic><topic>Keratolytic Agents - therapeutic use</topic><topic>Lichen Planus - drug therapy</topic><topic>Patient Selection</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Skin Diseases - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guenther, Lyn C.</creatorcontrib><creatorcontrib>Kunynetz, Rod</creatorcontrib><creatorcontrib>Lynde, Charles W.</creatorcontrib><creatorcontrib>Sibbald, R. Gary</creatorcontrib><creatorcontrib>Toole, John</creatorcontrib><creatorcontrib>Vender, Ronald</creatorcontrib><creatorcontrib>Zip, Catherine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Cutaneous Medicine and Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guenther, Lyn C.</au><au>Kunynetz, Rod</au><au>Lynde, Charles W.</au><au>Sibbald, R. Gary</au><au>Toole, John</au><au>Vender, Ronald</au><au>Zip, Catherine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acitretin Use in Dermatology</atitle><jtitle>Journal of Cutaneous Medicine and Surgery</jtitle><addtitle>J Cutan Med Surg</addtitle><date>2017-11</date><risdate>2017</risdate><volume>21</volume><issue>3_suppl</issue><spage>2S</spage><epage>12S</epage><pages>2S-12S</pages><issn>1203-4754</issn><eissn>1615-7109</eissn><abstract>Background:
Acitretin has been used for the treatment of severe psoriasis for over 20 years.
Objective:
The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation.
Methods:
A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. A panel of Canadian dermatologists developed a clinical pathway using a case-based approach, focusing on specific patient features.
Results:
The clinical pathway covers plaque psoriasis with hyperkeratotic plantar disease, palmoplantar pustulosis, hyperkeratotic hand dermatitis, lichen planus, lamellar ichthyosis, and hidradenitis suppurativa.
Conclusion:
The recommendations in our clinical pathway reflect the current use of acitretin in Canada for severe psoriasis and other disorders of keratinisation.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>28952335</pmid><doi>10.1177/1203475417733414</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1203-4754 |
| ispartof | Journal of Cutaneous Medicine and Surgery, 2017-11, Vol.21 (3_suppl), p.2S-12S |
| issn | 1203-4754 1615-7109 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1943650303 |
| source | Access via SAGE; MEDLINE |
| subjects | Acitretin - adverse effects Acitretin - therapeutic use Contraindications, Drug Hidradenitis Suppurativa - drug therapy Humans Ichthyosis, Lamellar - drug therapy Keratoderma, Palmoplantar - drug therapy Keratolytic Agents - adverse effects Keratolytic Agents - therapeutic use Lichen Planus - drug therapy Patient Selection Psoriasis Psoriasis - drug therapy Skin Diseases - drug therapy |
| title | Acitretin Use in Dermatology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A15%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acitretin%20Use%20in%20Dermatology&rft.jtitle=Journal%20of%20Cutaneous%20Medicine%20and%20Surgery&rft.au=Guenther,%20Lyn%20C.&rft.date=2017-11&rft.volume=21&rft.issue=3_suppl&rft.spage=2S&rft.epage=12S&rft.pages=2S-12S&rft.issn=1203-4754&rft.eissn=1615-7109&rft_id=info:doi/10.1177/1203475417733414&rft_dat=%3Cproquest_cross%3E2157487381%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157487381&rft_id=info:pmid/28952335&rft_sage_id=10.1177_1203475417733414&rfr_iscdi=true |